TrialThe lancet. Gastroenterology & hepatology2023

Withdrawal of infliximab or concomitant immunosuppressant therapy in patients with Crohn's disease on combination therapy (SPARE): a multicentre, open-label, randomised controlled trial.

Edouard Louis et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.